Amended  ||| S:0 E:8 ||| JJ
safety  ||| S:8 E:15 ||| NN
assessment  ||| S:15 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
dodecylbenzenesulfonate ||| S:29 E:52 ||| NN
,  ||| S:52 E:54 ||| ,
decylbenzenesulfonate ||| S:54 E:75 ||| NN
,  ||| S:75 E:77 ||| ,
and  ||| S:77 E:81 ||| CC
tridecylbenzenesulfonate  ||| S:81 E:106 ||| JJ
salts  ||| S:106 E:112 ||| NN
as  ||| S:112 E:115 ||| IN
used  ||| S:115 E:120 ||| VBN
in  ||| S:120 E:123 ||| IN
cosmetics  ||| S:123 E:133 ||| NNS
Sodium  ||| S:133 E:140 ||| JJ
dodecylbenzenesulfonate  ||| S:140 E:164 ||| NN
is  ||| S:164 E:167 ||| VBZ
one  ||| S:167 E:171 ||| CD
of  ||| S:171 E:174 ||| IN
a  ||| S:174 E:176 ||| DT
group  ||| S:176 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
salts  ||| S:185 E:191 ||| NN
of  ||| S:191 E:194 ||| IN
alkylbenzene  ||| S:194 E:207 ||| NNS
sulfonates  ||| S:207 E:218 ||| VBP
used  ||| S:218 E:223 ||| VBN
in  ||| S:223 E:226 ||| IN
cosmetics  ||| S:226 E:236 ||| NNS
as  ||| S:236 E:239 ||| IN
surfactant-cleansing  ||| S:239 E:260 ||| JJ
agents ||| S:260 E:266 ||| NNS
.  ||| S:266 E:268 ||| .
Sodium  ||| S:268 E:275 ||| JJ
dodecylbenzenesulfonate  ||| S:275 E:299 ||| NN
is  ||| S:299 E:302 ||| VBZ
soluble  ||| S:302 E:310 ||| VBN
in  ||| S:310 E:313 ||| IN
water  ||| S:313 E:319 ||| NN
and  ||| S:319 E:323 ||| CC
partially  ||| S:323 E:333 ||| RB
soluble  ||| S:333 E:341 ||| JJ
in  ||| S:341 E:344 ||| IN
alcohol ||| S:344 E:351 ||| NN
,  ||| S:351 E:353 ||| ,
with  ||| S:353 E:358 ||| IN
dermal  ||| S:358 E:365 ||| JJ
absorption  ||| S:365 E:376 ||| JJ
dependent  ||| S:376 E:386 ||| JJ
on  ||| S:386 E:389 ||| IN
pH ||| S:389 E:391 ||| JJ
.  ||| S:391 E:393 ||| .
Dodecylbenzenesulfonate  ||| S:393 E:417 ||| JJ
salts  ||| S:417 E:423 ||| NNS
are  ||| S:423 E:427 ||| VBP
not  ||| S:427 E:431 ||| RB
toxic  ||| S:431 E:437 ||| JJ
in  ||| S:437 E:440 ||| IN
single-dose  ||| S:440 E:452 ||| JJ
oral  ||| S:452 E:457 ||| JJ
and  ||| S:457 E:461 ||| CC
dermal  ||| S:461 E:468 ||| JJ
animal  ||| S:468 E:475 ||| NN
tests ||| S:475 E:480 ||| NNS
,  ||| S:480 E:482 ||| ,
and  ||| S:482 E:486 ||| CC
no  ||| S:486 E:489 ||| DT
systemic  ||| S:489 E:498 ||| JJ
toxicities  ||| S:498 E:509 ||| NN
were  ||| S:509 E:514 ||| VBD
observed  ||| S:514 E:523 ||| VBN
in  ||| S:523 E:526 ||| IN
repeat-dose  ||| S:526 E:538 ||| JJ
dermal  ||| S:538 E:545 ||| JJ
animal  ||| S:545 E:552 ||| NN
studies ||| S:552 E:559 ||| NNS
.  ||| S:559 E:561 ||| .
In  ||| S:561 E:564 ||| IN
dermal  ||| S:564 E:571 ||| JJ
animal  ||| S:571 E:578 ||| NN
studies ||| S:578 E:585 ||| NNS
,  ||| S:585 E:587 ||| ,
no  ||| S:587 E:590 ||| DT
evidence  ||| S:590 E:599 ||| NN
of  ||| S:599 E:602 ||| IN
reproductive  ||| S:602 E:615 ||| JJ
or  ||| S:615 E:618 ||| CC
developmental  ||| S:618 E:632 ||| JJ
toxicity  ||| S:632 E:641 ||| NN
was  ||| S:641 E:645 ||| VBD
reported ||| S:645 E:653 ||| VBN
.  ||| S:653 E:655 ||| .
At  ||| S:655 E:658 ||| IN
15 ||| S:658 E:660 ||| CD
%  ||| S:660 E:662 ||| NN
concentrations ||| S:662 E:676 ||| NNS
,  ||| S:676 E:678 ||| ,
sodium  ||| S:678 E:685 ||| JJ
dodecylbenzenesulfonate  ||| S:685 E:709 ||| NN
was  ||| S:709 E:713 ||| VBD
severely  ||| S:713 E:722 ||| RB
irritating  ||| S:722 E:733 ||| VBN
to  ||| S:733 E:736 ||| TO
rabbit  ||| S:736 E:743 ||| VB
skin ||| S:743 E:747 ||| NN
.  ||| S:747 E:749 ||| .
The  ||| S:749 E:753 ||| DT
Cosmetic  ||| S:753 E:762 ||| NNP
Ingredient  ||| S:762 E:773 ||| NNP
Review  ||| S:773 E:780 ||| NNP
Expert  ||| S:780 E:787 ||| NNP
Panel  ||| S:787 E:793 ||| NNP
concluded  ||| S:793 E:803 ||| VBD
that  ||| S:803 E:808 ||| IN
the  ||| S:808 E:812 ||| DT
irritant  ||| S:812 E:821 ||| JJ
properties  ||| S:821 E:832 ||| NNS
of  ||| S:832 E:835 ||| IN
these  ||| S:835 E:841 ||| DT
ingredients  ||| S:841 E:853 ||| NNS
are  ||| S:853 E:857 ||| VBP
similar  ||| S:857 E:865 ||| JJ
to  ||| S:865 E:868 ||| TO
those  ||| S:868 E:874 ||| DT
of  ||| S:874 E:877 ||| IN
other  ||| S:877 E:883 ||| JJ
detergents ||| S:883 E:893 ||| NNS
,  ||| S:893 E:895 ||| ,
with  ||| S:895 E:900 ||| IN
severity  ||| S:900 E:909 ||| JJ
dependent  ||| S:909 E:919 ||| JJ
on  ||| S:919 E:922 ||| IN
concentration  ||| S:922 E:936 ||| NN
and  ||| S:936 E:940 ||| CC
pH ||| S:940 E:942 ||| JJ
.  ||| S:942 E:944 ||| .
Products  ||| S:944 E:953 ||| NNS
containing  ||| S:953 E:964 ||| VBG
these  ||| S:964 E:970 ||| DT
ingredients  ||| S:970 E:982 ||| NNS
should  ||| S:982 E:989 ||| MD
be  ||| S:989 E:992 ||| VB
formulated  ||| S:992 E:1003 ||| VBN
to  ||| S:1003 E:1006 ||| TO
ensure  ||| S:1006 E:1013 ||| VB
that  ||| S:1013 E:1018 ||| IN
the  ||| S:1018 E:1022 ||| DT
irritancy  ||| S:1022 E:1032 ||| JJ
potential  ||| S:1032 E:1042 ||| NN
is  ||| S:1042 E:1045 ||| VBZ
minimized ||| S:1045 E:1054 ||| VBN
.  ||| S:1054 E:1056 ||| .
